ArticleAnnals of the rheumatic diseases2021
Interaction between the
Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Genetic and epigenetic determinants of relapse risk in lupus nephritis.Lupus science & medicine · 2026Article
- Systemic lupus erythematosus: from an adverse event of interferon administration to a disease with new treatment options.Upsala journal of medical sciences · 2025Review
- Age-stratified risk factors and predictive models for progression to lupus nephritis in patients with systemic lupus erythematosus: a review.Frontiers in immunology · 2025Review
- Effects of STAT4 on myocardial ischemia‑reperfusion injury and the underlying mechanisms.Molecular medicine reports · 2024Article
- Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients.Clinical rheumatology · 2024Review
- Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study.Rheumatology international · 2024Article
- Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals.Frontiers in medicine · 2024Article
- STAT4 gene polymorphisms in human diseases.Frontiers in immunology · 2024Review
- Treatment of lupus nephritis: consensus, evidence and perspectives.Nature reviews. Rheumatology · 2023Review
- Association of Immune-Related Genetic and Epigenetic Alterations with Lupus Nephritis.Kidney diseases (Basel, Switzerland) · 2022Review
- Transcriptome Studies in Lupus Nephritis.Archivum immunologiae et therapiae experimentalis · 2022Review
- GDF-15: A Potential Biomarker and Therapeutic Target in Systemic Lupus Erythematosus.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate how genetics influence the risk of smoking-related systemic lupus erythematosus (SLE) manifestations.
methodsPatients with SLE (n
resultsIn the discovery cohort, smoking was associated with myocardial infarction (MI) (OR 1.96 (95% CI 1.09 to 3.55)), with a greater effect in patients carrying any rs11889341
conclusionsSmoking in the presence of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.